| Hou, Ming |
NCT03998982: Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP |
|
|
| Recruiting | 4 | 30 | RoW | Glycyrrhetinic Acid, Dexamethasone | Shandong University | Immune Thrombocytopenia | 06/21 | 06/21 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT03692754: Atorvastatin in Management of Newly Diagnosed ITP |
|
|
| Not yet recruiting | 2/3 | 30 | RoW | Atorvastatin 20mg, atorvastatin calcium, Atorvastatin 10mg, Dexamethasone | Shandong University | Immune Thrombocytopenia, Purpura, Thrombocytopenic | 12/21 | 12/23 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
NCT05023915: A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP |
|
|
| Recruiting | 2 | 106 | RoW | dexamethasone, diammonium glycyrrhizinate enteric-coated capsule | Shandong University | Immune Thrombocytopenia | 08/21 | 07/22 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
NCT05020288: A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP |
|
|
| Not yet recruiting | 2 | 40 | NA | Orelabrutinib, ICP-022 | Shandong University | Immune Thrombocytopenia, Bruton's Tyrosine Kinase | 12/23 | 06/24 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04949009: Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP) |
|
|
| Recruiting | N/A | 400 | RoW | Avatrombopag, Doptelet | Shandong University | Primary Immune Thrombocytopenia | 10/21 | 03/22 | | |
| Li, Fei |
| Recruiting | 4 | 200 | RoW | Oral bifidobacterium triple live powder, Conventional treatment, Sunbathing, Sunbathing and the Oral bifidobacterium triple live powder | Zhuhai Center for Maternal and Child Health Care, Children's Hospital of Chongqing Medical University | Hyperbilirubinemia, Neonatal | 06/24 | 06/24 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/25 | 05/26 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
| Recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT05927792: Efficacy and Mechanism of Repetitive Transcranial Magnetic Stimulation in Children With Autism Spectrum Disorders |
|
|
| Recruiting | 2/3 | 200 | RoW | repeated transcranial magnetic stimulation (continuous theta-burst stimulation), sham repeated transcranial magnetic stimulation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Mental Health Center, Zhengzhou Children's Hospital, China, Qilu Hospital of Shandong University | Autism Spectrum Disorder | 09/25 | 12/25 | | |
wAIHA, NCT05535933: HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
|
|
| Recruiting | 2/3 | 110 | RoW | HMPL-523(300mg PO QD), Sovleplenib, Placebo | Hutchison Medipharma Limited | Warm Antibody Autoimmune Hemolytic Anemia | 09/26 | 11/26 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT03837873: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma |
|
|
| Recruiting | 2 | 118 | RoW | Rituximab, Etoposide, Vincristine, Doxorubicin, Dexamethasone, Cyclophosphamide, Lenalidomide, Cisplatin, Cytarabine | Institute of Hematology & Blood Diseases Hospital | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma | 09/23 | 09/24 | | |
NCT05147467: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 2 | 75 | RoW | APG2575 | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 09/24 | 12/24 | | |
NCT05320081: Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | CD30 CAR-T, Camrelizumab | Huazhong University of Science and Technology, The First Affiliated Hospital of Nanchang University | Lymphoma, Relapse/Recurrence | 12/23 | 06/24 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT06700798: Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial |
|
|
| Not yet recruiting | 2 | 90 | RoW | Orelabrutinib, ICP-022, rituximab, Cyclophosphamide, Vincristine, Prednisone tablet | Fei Li | Marginal Zone Lymphoma(MZL) | 05/26 | 12/27 | | |
NCT05933967: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 31 | RoW | Orelabrutinib+R-CHOP | Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Nanchang University | 12/24 | 12/26 | | |
NCT03634501: Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells |
|
|
| Recruiting | 1/2 | 200 | RoW | Activated NK | Xuanwu Hospital, Beijing | Lung Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer | 09/21 | 09/22 | | |
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 160 | US, RoW | SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine | Sellas Life Sciences Group, Sellas Life Sciences Group | Hematologic Malignancies | 06/25 | 12/25 | | |
NCT05667506: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) |
|
|
| Recruiting | 1/2 | 47 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 12/24 | 12/26 | | |
NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1/2 | 46 | RoW | YK012, YK012 for Injection | Excyte Biopharma Ltd | B-cell Acute Lymphoblastic Leukemia | 12/26 | 06/27 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies |
|
|
| Active, not recruiting | 1 | 15 | RoW | 3D189 | 3D Medicines | Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome | 12/24 | 12/24 | | |
| Recruiting | 1 | 108 | RoW | GLB-001, GLB-C183-A-2 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy | 12/26 | 12/27 | | |
| Recruiting | 1 | 48 | RoW | KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） | Rong Tao, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | 10/26 | 12/26 | | |
| Not yet recruiting | 1 | 137 | RoW | TQB3702 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hematologic Malignancy | 08/24 | 08/24 | | |
NCT06615193: A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor |
|
|
| Recruiting | 1 | 111 | RoW | HDM2005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy | 06/26 | 02/28 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
| Recruiting | 1 | 48 | RoW | TQB2928 Injection + Azacitidine for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 05/25 | 05/25 | | |
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
|
|
| Recruiting | 1 | 102 | RoW | APG-115, Azacitidine, Cytarabine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 12/25 | 12/25 | | |
NCT06010862: Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | CEA CAR-T cells | Chongqing Precision Biotech Co., Ltd, The First Affiliated Hospital of Nanchang University | Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer, Cholangiocarcinoma, Lung Cancer, Breast Cancer | 12/25 | 09/26 | | |
NCT06010875: A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 48 | RoW | CD70 CAR-T cells | Chongqing Precision Biotech Co., Ltd, The First Affiliated Hospital of Nanchang University | Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer | 12/25 | 09/26 | | |
NCT05472870: Efficacy and Mechanism of rTMS in Children With ASD: an Open-label Clinical Trial(Ⅱ) |
|
|
| Completed | N/A | 30 | RoW | repetitive Transcranial Magnetic Stimulation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Mental Health Center | Autism Spectrum Disorder | 12/22 | 01/23 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT05301556: Food for Special Medical Purpose in Patients With Digestive Tract Tumor |
|
|
| Completed | N/A | 326 | RoW | Experimental Product, Control Product | Abbott Nutrition | Gastrointestinal Cancer | 01/24 | 01/24 | | |
NACSOC, NCT02972541: Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer |
|
|
| Recruiting | N/A | 248 | RoW | Stenting with neoadjuvant chemotherapy, Stenting with immediate Surgery | Beijing Chao Yang Hospital | Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction | 12/23 | 12/23 | | |
NCT04327648: Effect and Mechanism of Social Interaction Treatment on ASD Children |
|
|
| Not yet recruiting | N/A | 90 | NA | Social interaction treatment, Neuronal cognition treatment, Routine treatment | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | ASD | 12/23 | 12/23 | | |
NCT04358744: The Real World Study of Autism Spectrum Disorder in China |
|
|
| Recruiting | N/A | 2500 | RoW | | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Autism Spectrum Disorder | 09/24 | 09/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma |
|
|
| Recruiting | N/A | 160 | RoW | No intervention | Takeda | Multiple Myeloma | 06/27 | 06/27 | | |
| Wang, Minggui |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT06569056: A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis |
|
|
| Recruiting | 3 | 578 | RoW | HRS-8427, Imipenem and Cilastatin Sodium, HRS-8427 placebo, Imipenem and Cilastatin Sodium placebo | Jiangsu HengRui Medicine Co., Ltd. | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | 11/25 | 11/25 | | |
